November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Switching to Subcutaneous Vedolizumab for IBD Maintenance: Real-World Outcomes

🔬 Research 1 min read 👁 4

A retrospective study indicates that transitioning inflammatory bowel disease patients from intravenous to subcutaneous vedolizumab maintenance therapy is generally safe and maintains disease stability.

Switching to Subcutaneous Vedolizumab for IBD Maintenance: Real-World Outcomes🔬Research

Photo: Nature Health Sciences

Key points

  • Transitioning to subcutaneous vedolizumab maintained stable disease activity in selected IBD patients.
  • Treatment persistence was 71% at the 48-week mark in the study cohort.
  • No serious systemic adverse events were documented, though some patients discontinued due to loss of response.

A recent retrospective study published in npj Autoimmunity examined the effectiveness and safety of switching patients with inflammatory bowel disease (IBD) from intravenous (IV) to subcutaneous (SC) vedolizumab maintenance therapy. The study followed 24 adults—including those with Crohn’s disease, ulcerative colitis, and indeterminate IBD—over a 48-week period. Researchers monitored clinical disease activity and biochemical markers, such as C-reactive protein and faecal calprotectin, at 12, 24, and 48 weeks.

Findings suggest that for patients already in remission at the time of the transition, the subcutaneous route provided stable disease control. While treatment persistence was 100% at week 12, it declined to 71% by week 48, with 29.2% of participants discontinuing the subcutaneous regimen, primarily due to a loss of response. No serious adverse events or systemic hypersensitivity reactions were reported, though one patient returned to IV therapy following an injection-site reaction.

What to know: This research was limited by a small sample size and its retrospective, single-centre design. While subcutaneous administration offers increased flexibility, patients should consult their gastroenterologist to determine if switching from intravenous infusions is appropriate for their specific clinical status.

Source Nature Health Sciences — nature.com/articles/s44483-026-00008-z ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.